Complexo Hospitalario Universitario de Santiago
Centro asistencial


Dana–Farber Cancer Institute
Boston, Estados UnidosPublicacións en colaboración con investigadores/as de Dana–Farber Cancer Institute (10)
2024
-
Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)
Nature Communications
-
Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)
Nature Communications
-
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe
Nature Communications, Vol. 15, Núm. 1
2021
-
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 1, pp. 113-124
2020
-
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
Genetic Epidemiology, Vol. 44, Núm. 5, pp. 442-468
2019
-
Adiponectin accounts for gender differences in hepatocellular carcinoma incidence
Journal of Experimental Medicine, Vol. 216, Núm. 5, pp. 1108-1119
-
Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)
Nature Communications
-
Novel common genetic susceptibility loci for colorectal cancer
Journal of the National Cancer Institute, Vol. 111, Núm. 2, pp. 146-157
2018
-
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
Nature Communications, Vol. 9, Núm. 1
-
Germline variation at 8q24 and prostate cancer risk in men of European ancestry
Nature Communications, Vol. 9, Núm. 1